| Net Cash Provided by (Used in) Operating Activities |
-108,142 |
USD |
-3.7% |
Q3 2025 |
Q1 2026 |
| Net Cash Provided by (Used in) Financing Activities |
100,000 |
USD |
|
Q3 2025 |
Q1 2026 |
| Common Stock, Shares Authorized |
500,000,000 |
shares |
-93.3% |
Q3 2025 |
Q1 2026 |
| Common Stock, Shares, Issued |
20,516,272 |
shares |
-93.1% |
Q3 2025 |
Q1 2026 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q3 2025 |
Q1 2026 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
-8,144 |
USD |
+64.4% |
Q3 2025 |
Q1 2026 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
6,437 |
USD |
-68.7% |
Q3 2025 |
Q1 2026 |
| Deferred Tax Assets, Valuation Allowance |
1,980,000 |
USD |
+5.5% |
Q2 2025 |
FY 2025 |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
-735,469 |
USD |
-4.3% |
Q3 2025 |
Q1 2026 |
| Additional Paid in Capital |
9,266,216 |
USD |
+6% |
Q3 2025 |
Q1 2026 |
| Deferred Tax Assets, Net of Valuation Allowance |
0 |
USD |
|
Q2 2025 |
FY 2025 |
| Interest Expense |
42,652 |
USD |
-4.4% |
Q3 2025 |
Q1 2026 |